Medicines Discovery Catapult to play an enabling role in support of UK life sciences industrial strategy:
Statement from Medicines Discovery Catapult
Responding to today’s announcement of the government’s Industrial Strategy for Life Sciences, Chris Molloy Chief Executive of the Medicines Discovery Catapult, said:
“The launch today (30th August 2017) of the Industrial Strategy for Life Sciences is a major boost for the sector and identifies a key delivery role for the Medicines Discovery Catapult, in support of the sector.
“By taking advantage of the expertise and national capabilities we are creating, the UK can advance more of its pipeline of targeted medicines, benefiting the UK’s economy and patient health.
“Seizing these opportunities will rely on us all adapting to rapid changes in global drug discovery and forging new collaborative forms of R&D. These will bring industry, medical research charities, academia and the services sector together to create a new supply chain of high-value drug prototypes and products, proven in patients.
“That’s where we help: whether by proving the benefits of new technologies or pathfinding faster routes to patient proof of concept studies, we can help the national community to draw on expertise, new resources and national infrastructure.
“The UK’s biotech, services and translational research community has huge potential at a pivotal time. This Life Sciences Strategy, enabled by the Catapult network, ensures the UK is well placed to enhance its heritage position as a global leader in new medicines.”
For further information or comment please contact Kate Beard or Louisa Struben at Amazon PR (working on behalf of Medicines Discovery Catapult) on 020 7700 6952 or email email@example.com.
NOTES TO EDITORS:
Chris Molloy, Chief Executive of Medicines Discovery Catapult, is available for further comment.
About Medicines Discovery Catapult
The Medicines Discovery Catapult is a new, national centre of applied Research and Development expertise to promote and support innovative, fast-to-patient drug discovery in the UK through collaborative projects across the community.
It is one of a network of elite, not-for-profit technology and innovation centres established by Innovate UK as a long-term investment in the UK’s economic capability. Medicines Discovery Catapult will work with industry, academic teams, technology experts, charities, regulators and others, to develop new approaches for the discovery and early development of new medicines helping to transform ideas into commercial products and services for the wider health and wealth of the country.
By developing and validating new ways of discovering new medicines, and promoting key talent and expertise across sectors, it can help the UK maintain its heritage position as a global leader in this key industry.